Biosimilars Council

Biosimilars Council
Name	Biosimilars Council
Type	Trade association
Founded	2015
Headquarters	United States
Parent organization	Generic Pharmaceutical Association

Biosimilars Council The Biosimilars Council is a trade association established to promote the development, approval, and uptake of biosimilar medicines in the United States. It operates within the pharmaceutical and healthcare policy ecosystem, interacting with regulatory bodies, manufacturers, payers, providers, and patient advocacy groups to influence market access and education for biologic alternatives.

History

The council emerged amid debates following passage of the Biologics Price Competition and Innovation Act of 2009 and the development of the regulatory pathway for biosimilar approvals administered by the Food and Drug Administration and influenced by precedent from the European Medicines Agency and regulatory practice in United Kingdom, Germany, and France. Founders included executives and policy staff from major pharmaceutical and biotechnology firms, trade organizations such as the Pharmaceutical Research and Manufacturers of America, and stakeholders active during the implementation of the Affordable Care Act and the rollout of the biosimilar regulatory framework. Early efforts corresponded with high-profile legal disputes involving companies like Amgen, Sandoz, Pfizer, and Samsung Bioepis over patent litigation and interchangeability, and with public discussions following approvals of biosimilars to products originally marketed by Genentech, Roche, AbbVie, and Johnson & Johnson.

Mission and Activities

The organization states its mission to advance policies and programs that foster biosimilar competition, increase patient access to biologic therapies, and lower healthcare spending associated with biologics. Activities include coordinating educational initiatives aimed at stakeholders such as prescribers affiliated with American Medical Association and institutions like Mayo Clinic and Cleveland Clinic, developing materials for pharmacy systems including CVS Health and Walgreens Boots Alliance, and hosting symposia with payers including Centers for Medicare & Medicaid Services and private insurers like UnitedHealth Group and Anthem, Inc.. The group publishes analyses referencing data sources such as the Institute for Clinical and Economic Review, the IQVIA, and the Kaiser Family Foundation to inform policymakers and the public about cost savings and real-world adoption metrics.

Organizational Structure

The council is governed by an executive committee and board composed of representatives from member companies and affiliated trade groups, often mirroring structures used by the Biotechnology Innovation Organization and other industry consortia. Leadership roles include an executive director and policy leads who liaise with regulatory agencies such as the FDA and legislative offices on Capitol Hill including committees like the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce. Subcommittees address topics ranging from clinical evidence and pharmacovigilance in collaboration with organizations such as the Centers for Disease Control and Prevention and the World Health Organization, to supply chain and contracting issues involving distributors like McKesson Corporation and wholesalers linked to AmerisourceBergen.

Policy and Advocacy

Advocacy priorities emphasize regulatory clarity for biosimilar interchangeability, patent litigation reforms including consideration of the Biologics Price Competition and Innovation Act of 2009 provisions, and reimbursement policies under programs like Medicare Part B and Medicaid. The council engages with lawmakers and agencies on proposed regulations from the Department of Health and Human Services, litigated precedents from the United States Court of Appeals for the Federal Circuit, and state-level pharmacy substitution laws promulgated by legislatures such as those in California, New York (state), and Texas. It also interacts with stakeholders in health technology assessment such as National Institute for Health and Care Excellence and with patient groups like National Patient Advocate Foundation to shape communications about biosimilar safety and efficacy.

Stakeholders and Membership

Members typically include multinational pharmaceutical firms, biotechnology companies, contract manufacturers, and service providers allied with entities such as Amgen, Novartis, Bristol-Myers Squibb, Eli Lilly and Company, and specialized biosimilar developers like Celltrion and Biocon. Other stakeholders encompass speciality pharmacies, hospital systems including Johns Hopkins Hospital, trade associations, and advocacy organizations representing clinicians and patients. The council often partners with research institutions including Harvard Medical School and policy think tanks such as the Brookings Institution to produce white papers and host convenings.

Controversies and Criticism

Critics have argued that industry-backed advocacy groups can prioritize commercial objectives over independent patient interests, drawing scrutiny similar to debates involving Pharmaceutical Research and Manufacturers of America and past controversies around lobbying by Big Pharma. Specific criticisms include concerns about messaging around interchangeability in the wake of litigation involving firms like Amgen and Sandoz, the potential influence on state substitution laws that involve pharmacy boards such as the National Association of Boards of Pharmacy, and the role of trade associations in shaping Medicare reimbursement policy. Patient advocacy groups and some healthcare economists, referencing analyses from the Commonwealth Fund and RAND Corporation, have at times questioned the magnitude of projected cost savings and the transparency of stakeholder communications. Legal and policy disputes over patent thickets, biosimilar market entry timing, and settlement agreements echo broader pharmaceutical industry controversies exemplified by cases involving Wyeth and Teva Pharmaceutical Industries.

Category:Pharmaceutical industry trade associations